Abaxis Inc. added a quantitative antibody test for canine Lyme disease to its line of tests available through the Abaxis Veterinary Reference Laboratories Division in Olathe, Kan., the company reported today.
The test measures a combination of antibodies to peptides which mimic certain antigens of the Borrelia burgdorferi spirochete. The antibodies are not found in vaccinated or noninfected patients, allowing for a definitive diagnosis of the disease, according to Kenneth Aron, Ph.D., Abaxis' chief technology officer.
The test may be used as a standalone diagnostic test to determine infection status or efficacy during treatment. It also may be used as a quantitative confirmation test for Abaxis’ upcoming VetScan Lyme Rapid Test, which is under development, according to the Union City, Calif.-based company.